Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial

Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial

BackgroundPatients with chronic kidney disease (CKD) are at high risk of developing heart failure and anemia, which is defined as type 4 cardiorenal-anemia syndrome (CRAS). CRAS aggravates the deterioration of both kidney and heart function, ultimately resulting in a high mortality. This study aims...

Full description

Bibliographic Details
Main Authors: Yumin Wen, Yang Xu, Hui Tian, Sizhu Jiang, Guofang Jiang, Puqing Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Medicine
Subjects:
cardiorenal-anemia syndrome
chronic kidney disease
anemia
heart failure
roxadustat
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.783387/full

Similar Items

Similar Items